Telomir Pharmaceuticals (TELO) Total Liabilities (2022 - 2026)
Telomir Pharmaceuticals (TELO) posted Total Liabilities of $1.4 million for Q4 2025, up 237.74% sequentially from $422807.0 in Q3 2025, and up 109.7% YoY from $680968.0 in Q4 2024.
Telomir Pharmaceuticals (TELO) Total Liabilities (2022 - 2026) Analysis & Trends
Telomir Pharmaceuticals has reported Total Liabilities for 4 years, with the latest figure at $1.4 million in Q4 2025.
- Quarterly Total Liabilities rose 109.7% year-over-year to $1.4 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $1.4 million (up 109.7% YoY) and the FY2025 annual result came in at $1.4 million, up 109.7% from the prior year.
- Total Liabilities improved to $1.4 million in Q4 2025 per TELO's latest filing, from $422807.0 in the prior quarter.
- Over five years, Total Liabilities peaked at $1.4 million in Q4 2025 and troughed at $348388.0 in Q2 2025.
- A 4-year average of $747463.8 and a median of $626102.5 in 2024 frame the typical range for Total Liabilities.
- The sharpest annual moves came in 2024 and 2025: Total Liabilities sank 49.01% in 2024, then jumped 109.7% in 2025.
- Over 4 years, Total Liabilities stood at $986008.0 in 2022, then soared by 35.45% to $1.3 million in 2023, then tumbled by 49.01% to $680968.0 in 2024, then surged by 109.7% to $1.4 million in 2025.
- According to Business Quant data, Total Liabilities over the past three periods registered $1.4 million, $422807.0, and $348388.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 7.18 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 10.02 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 1.62 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 4.20 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 4.00 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 4.20 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 1.35 Bn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 10.03 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 3.22 Bn |
| 10 | Telomir Pharmaceuticals | 68.14 Mn | 68.14 Mn | - | 332,424.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 332,424.00 |
| Dec 31, 2025 | 1.43 Mn |
| Sep 30, 2025 | 422,807.00 |
| Jun 30, 2025 | 348,388.00 |
| Mar 31, 2025 | 652,294.00 |
| Dec 31, 2024 | 680,968.00 |
| Sep 30, 2024 | 599,911.00 |
| Jun 30, 2024 | 534,155.00 |
| Mar 31, 2024 | 486,552.00 |
| Dec 31, 2023 | 1.34 Mn |
| Dec 31, 2022 | 986,008.00 |